These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 25851751)

  • 1. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatr Res; 2015 May; 64():88-98. PubMed ID: 25851751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
    Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.
    Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y
    Hum Psychopharmacol; 2014 Jan; 29(1):64-72. PubMed ID: 24424707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
    Pae CU; Wang SM; Han C; Lee SJ; Patkar AA; Masand PS; Serretti A
    J Psychiatry Neurosci; 2015 May; 40(3):174-86. PubMed ID: 25350320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.
    Rothschild AJ; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):858-66. PubMed ID: 22901736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine treatment for generalised anxiety disorder: a meta-analysis of anxiety, quality of life and safety outcomes.
    Qin B; Huang G; Yang Q; Zhao M; Chen H; Gao W; Yang M
    BMJ Open; 2019 Nov; 9(11):e033161. PubMed ID: 31784448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vortioxetine Treatment for Anxiety Disorder: A Meta-Analysis Study.
    Yee A; Ng CG; Seng LH
    Curr Drug Targets; 2018; 19(12):1412-1423. PubMed ID: 29149828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Simon JS
    Int J Clin Pract; 2014 Jan; 68(1):49-59. PubMed ID: 24341301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.
    Kasper S; Gastpar M; Müller WE; Volz HP; Möller HJ; Schläfke S; Dienel A
    Int J Neuropsychopharmacol; 2014 Jun; 17(6):859-69. PubMed ID: 24456909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of vortioxetine in working patients with generalized anxiety disorder.
    Christensen MC; Loft H; Florea I; McIntyre RS
    CNS Spectr; 2019 Apr; 24(2):249-257. PubMed ID: 29081307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.
    Orsolini L; Tomasetti C; Valchera A; Iasevoli F; Buonaguro EF; Vellante F; Fornaro M; Fiengo A; Mazza M; Vecchiotti R; Perna G; de Bartolomeis A; Martinotti G; Di Giannantonio M; De Berardis D
    Expert Rev Neurother; 2016 May; 16(5):483-95. PubMed ID: 27050932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
    Nomikos GG; Tomori D; Zhong W; Affinito J; Palo W
    CNS Spectr; 2017 Aug; 22(4):348-362. PubMed ID: 27869048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials.
    Berhan A; Barker A
    BMC Psychiatry; 2014 Sep; 14():276. PubMed ID: 25260373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
    McIntyre RS; Lophaven S; Olsen CK
    Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
    Fu J; Chen Y
    Psychopharmacology (Berl); 2015 Jan; 232(1):7-16. PubMed ID: 24871704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability.
    Adair M; Christensen MC; Florea I; Loft H; Fagiolini A
    J Affect Disord; 2023 May; 328():345-354. PubMed ID: 36708956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.